TrialArthritis research & therapy2011

Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS).

Jasmin B Kuemmerle-Deschner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.